# Amylyx Pharmaceuticals share price today (Amylyx Pharmaceuticals, Inc., AMLX)

> Amylyx Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AMLX · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/amlx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $29.20 (+109.6% in a year)
- Revenue (Dec 2024): −$665 K (−100.6% on a year ago)
- Profit (Dec 2024): −$37.5 M (−893.6% on a year ago)
- Operating margin: 6,113.4% (+6,111.6 points on a year ago)

The main question: the share price moved +109.6% in a year while yearly earnings per share moved −732.6%. The difference came from the market paying a higher multiple. ## What is the Amylyx Pharmaceuticals share price today? Amylyx Pharmaceuticals, Inc.'s share price was $29.20 at the close on 3 November 2026. It has been rising for 22 weeks. That is 44.3% above its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $39, and at that close it sat 65% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 16 weeks in a row. Over the last 4.8 years the share price moved +42% while the S&P 500 moved +62%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Amylyx Pharmaceuticals pay? Amylyx Pharmaceuticals, Inc. pays no dividend. In the last 11 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Amylyx Pharmaceuticals on? Amylyx Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Amylyx Pharmaceuticals profitable? Amylyx Pharmaceuticals, Inc. posted a net loss of $37.5 M in the Dec 2024 quarter. The full FY24 year was a loss of $302 M. That loss is 5,646.0% of the quarter's revenue. The same quarter a year earlier earned $4.7 M. 7 of the last 11 reported quarters were loss-making. Dec 2024 profit was −$37.5 M, −893.6% on a year earlier. For the full year, FY24 profit was −$302 M (−712.4% on the year before). Why profit moved: revenue changed −100.6% on a year earlier and the margin moved +6,111.6 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −2,355.7% and revenue −69.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Amylyx Pharmaceuticals make, and is it growing? Amylyx Pharmaceuticals, Inc. reported −$665 K of revenue in the Dec 2024 quarter, −100.6% on the same quarter a year earlier. Over 3 years it has grown 574.3% a year on average. The last full year, FY24, came in at $87.4 M. The last four reported quarters add to $87.4 M. FY24 revenue was $87.4 M, −77.1% on the year before. Recent pace: the last four quarters grew −69.3% on average, against 574.3% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Amylyx Pharmaceuticals keep? Amylyx Pharmaceuticals, Inc.'s operating margin was 6,113.4% in the Dec 2024 quarter, 6,111.6 percentage points higher than the same quarter a year ago. Across 4 years it has been between −29,013.3% and 10.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +6,111.6 percentage points on the year while gross margin changed +3,492.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Amylyx Pharmaceuticals' profit turning into cash? Amylyx Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used $168 M of cash, against −$302 M of profit. After $36.4 M of spending on assets, free cash was −$204 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Amylyx Pharmaceuticals' cash go? Amylyx Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $40.1 M on assets over the last 3 years. Averaged over those years that is 15.3% of FY24 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $40.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Amylyx Pharmaceuticals' P/E ratio, and how does it compare with its own history? Amylyx Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Amylyx Pharmaceuticals, Inc. at 41.9× its FY24 revenue of $87.4 M. The P/E comes back here once profit turns positive. Why the multiple is where it is: over the past year earnings per share moved −732.6% while the price moved +109.6%. The price did better than earnings, which pushed the multiple up within its own range. ## Is the Amylyx Pharmaceuticals business getting better or worse? Amylyx Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 6 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Amylyx Pharmaceuticals earn on its capital? Amylyx Pharmaceuticals, Inc. earned a ROE of −183% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −1,155%, a number that says nothing useful about the business. It comes from a −345.4% net margin and 0.45× asset turnover (sales divided by assets). Why the return is what it is (FY24): a −345.4% net margin × 0.45× asset turnover × 1.18× leverage (assets divided by equity) ≈ −183.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Amylyx Pharmaceuticals have too much debt? Amylyx Pharmaceuticals, Inc. has total debt of $5.3 M against shareholder equity of $239 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.02 in FY22 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Amylyx Pharmaceuticals shareholding pattern? 12.1% of Amylyx Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Amylyx Pharmaceuticals from balance-sheet trouble? For Amylyx Pharmaceuticals, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Amylyx Pharmaceuticals rank in its industry? 48.7 out of 100, rank 27 of 28 in Drug Manufacturers - Specialty & Generic, with 40% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Amylyx Pharmaceuticals, Inc. scores 48.7 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 27. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 17.4 + 5.6 + 9.9 + 15.8 = 48.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Amylyx Pharmaceuticals compared with? Amylyx Pharmaceuticals ranks 27 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 48.7 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative
12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. Amylyx Pharmaceuticals, Inc. this page AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue n/a · Profit n/a · Operating margin change -9503.3 points · 6% evidence Capital efficiency 5.6/25 · ROCE -66.6% · Operating margin n/a · 61% evidence Valuation 9.9/20 · P/E 20.2× · PEG n/a · 15% evidence Relative strength 15.8/20 · Lead over its industry 34.9% · Lead over S&P 500 49.7% · 1 year 137.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 5.6 + 9.9 + 15.8 = 48.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Amylyx Pharmaceuticals in size? Amylyx Pharmaceuticals is the 16th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Lantheus Holdings, Inc., Hims & Hers Health, Inc. and Liquidia Corporation. Just below it: Indivior Pharmaceuticals, Inc., Bausch Health Companies Inc. and HUTCHMED (China). ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) $6.6 billion
2. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) $6 billion
3. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) $3.8 billion
4. Amylyx Pharmaceuticals, Inc. $3.7 billion
5. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) $3.3 billion
6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) $3 billion
7. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) $2.4 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [ACADIA Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/acad) $3.5 billion · Biotechnology
2. [Broadstone Net Lease, Inc.](https://www.sectoralpha.in/us/stocks/bnl) $3.5 billion · REIT - Diversified
3. Amylyx Pharmaceuticals, Inc. $3.5 billion
4. [Highwoods Properties, Inc.](https://www.sectoralpha.in/us/stocks/hiw) $3.5 billion · REIT - Office
5. [Curbline Properties Corp.](https://www.sectoralpha.in/us/stocks/curb) $3.5 billion · REIT - Retail

## What else do people ask about Amylyx Pharmaceuticals? ### What were Amylyx Pharmaceuticals's latest quarterly results? Amylyx Pharmaceuticals, Inc. reported revenue of −$665 K and a net loss of $37.5 M for the Dec 2024 quarter. Revenue fell 100.6% and profit fell 893.6% compared with a year earlier. Earnings per share were −$0.55. The operating margin was 6,113.4%, 6,111.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Amylyx Pharmaceuticals's market cap? Amylyx Pharmaceuticals, Inc.'s market capitalisation is $3.7 B at a stock price of $29.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Amylyx Pharmaceuticals performing? Amylyx Pharmaceuticals, Inc.'s share price has been rising for 22 weeks. In its latest quarter, revenue fell 100.6% and profit fell 893.6% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 16 weeks running (as of 3 November 2026). ### Will Amylyx Pharmaceuticals's stock price go up? This page does not forecast Amylyx Pharmaceuticals, Inc.'s stock price. What it shows instead: the stock price is $29.20, and it has been rising for 22 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Amylyx Pharmaceuticals in its business cycle? Amylyx Pharmaceuticals, Inc.'s FY24 operating margin was −292.6%, against a 4-year range of −29,013.3% to 10.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 6,113.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Amylyx Pharmaceuticals story? The main question: the share price moved +109.6% in a year while yearly earnings per share moved −732.6%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Amylyx Pharmaceuticals a stock worth studying right now? What the numbers show: Amylyx Pharmaceuticals, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.